1-methyl-7-[(3,3,3-trifluoro)propylamino]-1,3-dihydro-2H-benzimidazol-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 1-methyl-7-[(3,3,3-trifluoro)propylamino]-1,3-dihydro-2H-benzimidazol-2-one
• 英文别名: 3-methyl-4-(3,3,3-trifluoropropylamino)-1H-benzimidazol-2-one
• 化学式: C₁₁H₁₂F₃N₃O
• 分子量: 259.231
• InChiKey: QHZJLIZEOVYLAK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  44.4
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-methyl-7-[(3,3,3-trifluoro)propylamino]-1,3-dihydro-2H-benzimidazol-2-one 在 N-溴代丁二酰亚胺(NBS) 、 sodium cyanoborohydride 、 溶剂黄146 、 三氯氧磷 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 32.0h， 生成 2-chloro-4-bromo-N-ethyl-1-methyl-N-(3,3,3-trifluoropropyl)-1H-benzimidazol-7-amine
  参考文献：
  名称：

  Discovery of 4-chloro-2-(2,4-dichloro-6-methylphenoxy)-1-methyl-7-(pentan-3-yl)-1H-benzimidazole, a novel CRF1 receptor antagonist

  摘要：

  Compound 1 exhibits potent binding inhibition activity against a corticotropin-releasing factor 1 (CRF1) receptor (IC50 = 9.5 nM) and in vitro antagonistic activity (IC50 = 88 nM) but is rapidly metabolized by human hepatic microsomes (182 mu L/min/mg). Here we identified metabolically stable compounds with potent CRF binding inhibitory activity. Structure-activity relationship (SAR) studies considering win vitro metabolic stability revealed that 4-chloro-2-(2,4-dichloro-6-methylphenoxy)-1-methyl-7-(pentan-3-yl)-1H-benzimidazole 24d was more stable in human microsomes (87 mu L/min/mg) than compound 1. Compound 24d demonstrated potent CRF1 binding inhibitory activity (IC50 = 4.1 nM), in vitro antagonistic activity (IC50 = 44 nM), and slow dissociation from the CREI receptor. Orally administered compound 24d (6-24 mu mol/kg) showed ex vivo CRF1 receptor binding in the rat pituitary, olfactory bulb, and frontal cortex and suppressed stress-induced adrenocorticotropic hormone (ACTH) secretion. In this report, we discuss SAR studies on the metabolic stability as well as CRF binding inhibitory activity of the benzimidazole series as CRF1 receptor antagonists and the pharmacological profiles of compound 24d. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2016.11.011
• 作为产物：
  描述：

  7-amino-1-methyl-1,3-dihydro-2H-benzimidazol-2-one 、 2,2,2-三氟乙醛 在 sodium cyanoborohydride 、 溶剂黄146 作用下， 以 甲醇 为溶剂， 反应 15.0h， 以94%的产率得到1-methyl-7-[(3,3,3-trifluoro)propylamino]-1,3-dihydro-2H-benzimidazol-2-one
  参考文献：
  名称：

  Discovery of 4-chloro-2-(2,4-dichloro-6-methylphenoxy)-1-methyl-7-(pentan-3-yl)-1H-benzimidazole, a novel CRF1 receptor antagonist

  摘要：

  Compound 1 exhibits potent binding inhibition activity against a corticotropin-releasing factor 1 (CRF1) receptor (IC50 = 9.5 nM) and in vitro antagonistic activity (IC50 = 88 nM) but is rapidly metabolized by human hepatic microsomes (182 mu L/min/mg). Here we identified metabolically stable compounds with potent CRF binding inhibitory activity. Structure-activity relationship (SAR) studies considering win vitro metabolic stability revealed that 4-chloro-2-(2,4-dichloro-6-methylphenoxy)-1-methyl-7-(pentan-3-yl)-1H-benzimidazole 24d was more stable in human microsomes (87 mu L/min/mg) than compound 1. Compound 24d demonstrated potent CRF1 binding inhibitory activity (IC50 = 4.1 nM), in vitro antagonistic activity (IC50 = 44 nM), and slow dissociation from the CREI receptor. Orally administered compound 24d (6-24 mu mol/kg) showed ex vivo CRF1 receptor binding in the rat pituitary, olfactory bulb, and frontal cortex and suppressed stress-induced adrenocorticotropic hormone (ACTH) secretion. In this report, we discuss SAR studies on the metabolic stability as well as CRF binding inhibitory activity of the benzimidazole series as CRF1 receptor antagonists and the pharmacological profiles of compound 24d. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2016.11.011

文献信息

• [EN] NITROGEN-CONTAINING FUSED RING COMPOUND<br/>[FR] COMPOSÉ À CYCLES FUSIONNÉS CONTENANT DE L'AZOTE
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2010032461A1

  公开（公告）日：2010-03-25

  次式（Ｉ） ［式中、 Ｒ１は、各出現において、同一または異なって、水素原子、ハロゲン原子、置換基を有していてもよい炭化水素基、置換基を有していてもよい複素環基、置換基を有していてもよいアルコキシ基、水酸基、または置換基を有していてもよいアミノ基を表し； Ｒ２は、水素原子、または置換基を表し； Ｒ３は、水素原子、または置換基を表し； 環Ａは、置換基を有していてもよい炭素環、または置換基を有していてもよい複素環を表し； ｎは１～４の整数を表す。］で示される化合物もしくはその塩またはそれらのプロドラッグを含有する酸分泌抑制剤。
• Discovery of 4-chloro-2-(2,4-dichloro-6-methylphenoxy)-1-methyl-7-(pentan-3-yl)-1H-benzimidazole, a novel CRF1 receptor antagonist
  作者：Michiyo Mochizuki、Takuto Kojima、Katsumi Kobayashi、Etsuo Kotani、Yuji Ishichi、Naoyuki Kanzaki、Hideyuki Nakagawa、Teruaki Okuda、Yohei Kosugi、Takahiko Yano、Yuu Sako、Maiko Tanaka、Kazuyoshi Aso

  DOI：10.1016/j.bmc.2016.11.011

  日期：2017.3

  Compound 1 exhibits potent binding inhibition activity against a corticotropin-releasing factor 1 (CRF1) receptor (IC50 = 9.5 nM) and in vitro antagonistic activity (IC50 = 88 nM) but is rapidly metabolized by human hepatic microsomes (182 mu L/min/mg). Here we identified metabolically stable compounds with potent CRF binding inhibitory activity. Structure-activity relationship (SAR) studies considering win vitro metabolic stability revealed that 4-chloro-2-(2,4-dichloro-6-methylphenoxy)-1-methyl-7-(pentan-3-yl)-1H-benzimidazole 24d was more stable in human microsomes (87 mu L/min/mg) than compound 1. Compound 24d demonstrated potent CRF1 binding inhibitory activity (IC50 = 4.1 nM), in vitro antagonistic activity (IC50 = 44 nM), and slow dissociation from the CREI receptor. Orally administered compound 24d (6-24 mu mol/kg) showed ex vivo CRF1 receptor binding in the rat pituitary, olfactory bulb, and frontal cortex and suppressed stress-induced adrenocorticotropic hormone (ACTH) secretion. In this report, we discuss SAR studies on the metabolic stability as well as CRF binding inhibitory activity of the benzimidazole series as CRF1 receptor antagonists and the pharmacological profiles of compound 24d. (C) 2016 Elsevier Ltd. All rights reserved.